This is a preview of subscription content, log in via an institution to check access.
Notes
Funded by Ipsen Pharma.
Reference
Fust K, et al. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics : 11 Mar 2020. Available from: URL: http://dx.doi.org/10.1007/s40273-020-00896-5
Rights and permissions
About this article
Cite this article
Telotristat ethyl "affordable" addition to standard carcinoid syndrome care in Sweden. PharmacoEcon Outcomes News 849, 29 (2020). https://doi.org/10.1007/s40274-020-6680-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6680-1